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1. INTRODUCTION {#jcmm15589-sec-0001}
===============

Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide,[^1^](#jcmm15589-bib-0001){ref-type="ref"} resulting in sudden myocardial tissue ischaemia, and sudden cardiac death.[^2^](#jcmm15589-bib-0002){ref-type="ref"} Thus, it is necessary to identify novel biomarkers for early diagnosis and prognosis prediction of AMI, as these may assist in providing valuable therapies.

Long non‐coding RNAs (lncRNAs) are defined as non--protein‐coding transcripts that are longer than 200 nucleotides. An increasing body of evidence suggested that lncRNAs play biologically fundamental roles in the occurrence and development of cardiovascular diseases.[^3^](#jcmm15589-bib-0003){ref-type="ref"}, [^4^](#jcmm15589-bib-0004){ref-type="ref"}, [^5^](#jcmm15589-bib-0005){ref-type="ref"} LncRNAs are differently expressed and have been shown to be used as biomarkers for the progression of coronary artery disease, atrial fibrillation and heart failure.[^6^](#jcmm15589-bib-0006){ref-type="ref"}, [^7^](#jcmm15589-bib-0007){ref-type="ref"}, [^8^](#jcmm15589-bib-0008){ref-type="ref"} In addition, lncRNAs might act as biomarkers in the early diagnosis of AMI and also help in predicting its outcome.[^9^](#jcmm15589-bib-0009){ref-type="ref"}, [^10^](#jcmm15589-bib-0010){ref-type="ref"}, [^11^](#jcmm15589-bib-0011){ref-type="ref"} Compared with lncRNAs present in extracellular fluids of the body, those lncRNAs that are packaged in exosomes are highly stable. Exosomal lncRNAs have lipid bilayers and could protect them from enzymatic degradation of RNA enzymes in bodily fluids. Thus, exosomal lncRNAs have a relatively long and stable duration of expression in the cardiovascular system. Previous studies have shown that exosomal lncRNAs were involved in various diseases and can be used as biomarkers.[^12^](#jcmm15589-bib-0012){ref-type="ref"}, [^13^](#jcmm15589-bib-0013){ref-type="ref"}, [^14^](#jcmm15589-bib-0014){ref-type="ref"} However, few reports have focused on the role of exosomal lncRNAs in AMI. Hence, in the present study, we investigated the role of circulating exosomal lncRNAs in AMI patients and provide some potential biomarkers for diagnosis and prognosis prediction of AMI.

2. STUDY PATIENTS AND METHODS {#jcmm15589-sec-0002}
=============================

2.1. Study patients {#jcmm15589-sec-0003}
-------------------

The present study compared the sequencing profiles of circulating exosomal lncRNA in AMI patients (n = 15) with controls (n = 15). This was first validated in 20 AMI patients and 20 controls, and then second validation in 85 AMI patients and 48 controls. For sequencing profiles, the blood samples of every 5 AMI patients as well as the controls were pooled into one sample, and thus, '3 AMI' and '3 control' samples were profiled. All AMI patients enrolled in the present study had a heart attack within 12 hours from the time of admission, and revascularization was successfully performed in the emergency department before hospitalization.

AMI was defined based on clinical symptoms, typical changes in electrocardiogram (ECG), elevated cardiac biomarkers troponin‐I (TnI) and creatine kinase MB (CKMB) given by the Universal Definition of myocardial infarction.[^15^](#jcmm15589-bib-0015){ref-type="ref"} The controls included were of non‐coronary chest pain patients (NCCP), that had chest pain, normal cardiac biomarkers and most importantly, no coronary stenosis as confirmed by angiography.

All patients were recruited from Beijing Chao‐Yang Hospital Affiliated to Capital Medical University in China. Written informed consent was obtained and signed from all participants. This study was conducted in accordance with the Declaration of Helsinki, and the research protocol was approved by the Ethics Committee of Beijing Chao‐Yang Hospital.

2.2. Exosomal Isolation and Identification {#jcmm15589-sec-0004}
------------------------------------------

The exosomes were isolated using a commercial kit (Qiagen Inc), following the manufacturer\'s instructions, and identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and Western blotting. Isolated exosomes were examined by TEM and NTA as described previously.[^16^](#jcmm15589-bib-0016){ref-type="ref"}, [^17^](#jcmm15589-bib-0017){ref-type="ref"} Western blotting of exosomal marker protein CD63 (Abcam) and heat shock protein 70 (HSP70) (Abcam) was done as previously described.[^18^](#jcmm15589-bib-0018){ref-type="ref"}

2.3. Exosomal RNA Extraction, RNA Sequencing and Quantitative RT‐PCR {#jcmm15589-sec-0005}
--------------------------------------------------------------------

The lncRNAs were extracted from exosomes by using a commercial kit (Qiagen Inc) according to the manufacturer\'s protocol. RNA sequencing procedure was done as described in the methods section of our previous study.[^19^](#jcmm15589-bib-0019){ref-type="ref"} The relative expression levels of lncRNA were quantified using ViiA 7 Real‐Time PCR System (Applied Biosystems) according to standard methods, and the forward and reverse primers included were listed in Table [S1](#jcmm15589-sup-0001){ref-type="supplementary-material"}. The lncRNA IDs were searched in Ensembl Human GRCh37.p13.

2.4. Laboratory measurements and echocardiography {#jcmm15589-sec-0006}
-------------------------------------------------

Fasting venous blood samples were taken within the first 24 hours of admission. Blood samples for isolating the exosomes were collected by venipuncture into EDTA containing tubes. All patients received laboratory measurements including lipids, glucose, creatinine and other items. Echocardiography was performed within 72 hours after admission. The items measured included left ventricular end‐diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and others.

2.5. Clinical conditions {#jcmm15589-sec-0007}
------------------------

Heart failure was defined by NT‐BNP \> 1000 pg/mL, or LVEDD \> 55 mm, or LVEF \< 40%. Major adverse cardiovascular events (MACE) included cardiac death, ventricular fibrillation and cardiac shock. Long‐term hospitalized was defined as hospital time \> 5 days.

2.6. Statistical analysis {#jcmm15589-sec-0008}
-------------------------

All analyses were performed using SPSS 24.0 software (IBM). Continuous variables with normal distribution were expressed as mean ± standard deviation (SD) and compared by two‐sample *t* test, while those with non‐normal distributed were expressed as quartiles and compared by Mann‐Whitney *U* test. Categorical variables were expressed as percentages and numbers, and compared using the chi‐square test. Spearman\'s correlation coefficients were used to assess the relationships between variables. Receiver operating characteristic curves and areas under the curve (AUCs) were computed. All statistical tests were two‐tailed, and *P*‐values of .05 were considered to be statistically significant.

3. RESULTS {#jcmm15589-sec-0009}
==========

3.1. Sequencing profiles of circulating exosomal lncRNA in AMI patients {#jcmm15589-sec-0010}
-----------------------------------------------------------------------

The clinical characteristics of sequencing samples are provided in Table [S2](#jcmm15589-sup-0001){ref-type="supplementary-material"}. There were mostly well balanced between AMI patients and controls, except for the higher fasting glucose level in AMI patients. Given that the number of diabetics was the same in the two groups, the higher fasting glucose level in AMI patients was considered to be caused by stressed hyperglycaemia.

Exosomes from next‐generation sequencing of plasma samples were characterized by TEM, nanoparticle tracking analysis and Western blotting. TEM analysis (Figure [1A](#jcmm15589-fig-0001){ref-type="fig"}) revealed that the exosomes had circular‐like, bilayer membrane vesicle structure and were around 100 nm in diameter according to nanoparticle tracking analysis (Figure [1B](#jcmm15589-fig-0001){ref-type="fig"}). Western blot analysed the expression of specific proteins CD63 and HSP70 (Figure [1C](#jcmm15589-fig-0001){ref-type="fig"}), indicating exosomal marker protein in plasma samples.

![Exosome identification for sequencing plasma samples by TEM (A), nanoparticle tracking analysis (B) and Western blotting (C), respectively. TEM: transmission electron microscopy; AMI, acute myocardial infarction; and HSP70, heat shock protein 70](JCMM-24-9388-g001){#jcmm15589-fig-0001}

Using a twofold expression difference as a cut‐off, a total of 518 differentially expressed lncRNAs were detected in the plasma exosomes of the two groups with 245 up‐regulated lncRNAs and 273 down‐regulated lncRNAs (*P* \< .05; Figure [2A](#jcmm15589-fig-0002){ref-type="fig"}). From the 245 up‐regulated lncRNAs identified, six highly expressed lncRNAs with top fold change were selected for the first validation (Figure [2B](#jcmm15589-fig-0002){ref-type="fig"}).

![Circulating exosomal lncRNA sequencing in AMI. A: the hierarchical clustering of substantially differentially expressed (*P* \< .05; fold change \> 2) lncRNAs in control and AMI; B: Six up‐regulated lncRNAs in AMI were selected for the first validation. AMI, acute myocardial infarction](JCMM-24-9388-g002){#jcmm15589-fig-0002}

3.2. First validation of circulating exosomal lncRNA {#jcmm15589-sec-0011}
----------------------------------------------------

The first validation was performed in 20 AMI patients and 20 controls, and their clinical characteristics are shown in Table [1](#jcmm15589-tbl-0001){ref-type="table"}. The results showed no differences between the two groups in age, physical data (including heart rate \[HR\], systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], body mass index \[BMI\]), historical data (including history of hypertension and diabetes, and family history) and living habits (including smoking and drinking). The circulating exosomal lncRNA ENST00000553425.1, lncRNA ENST00000556024.1, lncRNA ENST00000556899.1, lncRNA ENST00000597609.1, lncRNA ENST00000603310.1 and lncRNA ENST00000575985.1 were selected, which were highly expressed in both groups with top fold change, to perform the first validation, while lncRNA ENST00000553425.1 (*P* = .046, fold change = 1.60), lncRNA ENST00000556899.1 (*P* = .010, fold change = 3.13), lncRNA ENST00000603310.1 (*P* = .040, fold change = 1.69) and lncRNA ENST00000575985.1 (*P* = .014, fold change = 3.11) showed significant up‐regulation in AMI patients in the first validation (Figure [3](#jcmm15589-fig-0003){ref-type="fig"}). Using a twofold expression difference as a cut‐off, lncRNA ENST00000556899.1 and lncRNA ENST00000575985.1 were selected for subsequent second validation.

###### 

Clinical characteristics of patients in the first and second validations in controls and patients with AMI

                                    First validation          Second validation                                                                 
  --------------------------------- ------------------------- ------------------------ -------- ----------------------- ----------------------- --------
  Age, y                            55.9 ± 11.1               59.8 ± 15.0              .356     56.6 ± 10.8             59.4 ± 10.7             .155
  Male, n (%)                       9 (45.0)                  17 (85.0)                .008     27 (56.3)               77 (90.6)               \<.001
  Current smoker, n (%)             8 (40.0)                  9 (45.0)                 .530     4 (8.3)                 57 (67.1)               \<.001
  Current drinker, n (%)            3 (15.0)                  8 (40.0)                 .077     11 (22.9)               25 (29.4)               .271
  Physical data                                                                                                                                 
  Heart rate, beats/min             72.0 \[65.0‐73.0\]        72.5 \[65.3‐78.8\]       .327     71.0 \[63.8‐79.8\]      76.0 \[67.0‐87.0\]      .037
  Systolic blood pressure, mm Hg    129.5 \[119.5‐136.0\]     122.0 \[110.0‐132.3\]    .149     128.5 \[120.3‐140.0\]   121.0 \[112.5‐136.5\]   .081
  Diastolic blood pressure, mm Hg   72.5 \[66.3‐81.3\]        68.5 \[58.5‐80.5\]       .165     77.5 \[70.0‐84.8\]      74.0 \[66.5‐81.5\]      .429
  Body mass index, kg/m^2^          24.7 ± 4.1                25.2 ± 1.0               .552     26.1 ± 3.5              25.3 ± 2.6              .135
  Historical data                                                                                                                               
  Hypertension, n (%)               7 (35.0)                  10 (50.0)                .337     19 (39.6)               48 (56.5)               .061
  Diabetes, n (%)                   0 (0.0)                   2 (10.0)                 .468     5 (10.4)                20 (23.5)               .063
  Family history, n (%)             3 (15.0)                  6 (30.0)                 .449     13 (27.1)               20 (23.5)               .649
  Laboratory data                                                                                                                               
  C‐reactive protein, mg/L          1.51 \[0.82‐2.24\]        2.86 \[1.34‐11.54\]      .026     1.10 \[0.59‐2.57\]      6.46 \[2.44‐13.00\]     \<.001
  ESR, mm/h                         3.00 \[2.00‐6.00\]        4.50 \[2.00‐10.50\]      .497     5.00 \[2.00‐10.50\]     6.00 \[3.00‐13.00\]     .186
  Leukocyte, ×10^9^/L               5.95 \[5.46‐7.17\]        8.55 \[6.67‐11.40\]      .003     5.90 \[5.33‐7.25\]      9.34 \[7.03‐11.51\]     \<.001
  Neutrophil, ×10^9^/L              3.40 \[2.89‐4.25\]        6.03 \[4.07‐9.09\]       \<.001   3.73 \[3.12‐4.52\]      7.12 \[4.95‐10.34\]     \<.001
  Lymphocyte, ×10^9^/L              2.00 \[1.65‐2.30\]        1.47 \[0.98‐1.68\]       \<.001   1.67 \[1.47‐2.07\]      1.60 \[1.00‐2.25\]      .19
  Hemoglobin, g/L                   124 0.0 \[117.5‐137.0\]   137.0 \[121.3‐145.0\]    .114     134.5 \[124.3‐147.8\]   141.0 \[130.0‐156.0\]   .026
  Platelets, ×10^9^/L               246.0 \[209.5‐266.5\]     212.0 \[179.5‐268.5\]    .253     213.0 \[185.5‐259.0\]   200.0 \[167.0‐244.5\]   .304
  AST, U/L                          18.0 \[16.0‐22.8\]        61.5 \[24.0‐214.0\]      \<.001   19.0 \[17.0‐22.5\]      43.0 \[26.0‐146.5\]     \<.001
  ALT, U/L                          15.5 \[12.0‐23.3\]        28.5 \[17.3‐48.0\]       .007     16.0 \[12.0‐21.5\]      30.0 \[19.5‐47.0\]      \<.001
  Total cholesterol, mmol/L         4.28 \[3.53‐4.42\]        4.59 \[4.21‐5.13\]       .091     4.22 \[3.58‐5.18\]      4.38 \[3.50‐5.31\]      .785
  HDL‐C, mmol/L                     1.15 \[0.93‐1.58\]        1.00 \[0.90‐1.38\]       .398     1.10 \[0.95‐1.30\]      1.05 \[0.80‐1.24\]      .114
  LDL‐C, mmol/L                     2.25 \[1.90‐2.73\]        2.85 \[2.43‐3.28\]       .015     2.70 \[1.95‐3.20\]      2.57 \[2.00‐3.51\]      .548
  Triglycerides, mmol/L             1.28 \[0.79‐1.75\]        1.44 \[0.83‐1.81\]       .602     1.25 \[0.99‐1.80\]      1.51 \[1.07‐2.45\]      .018
  Fast glucose, mmol/L              5.06 \[4.62‐5.32\]        5.56 \[5.08‐8.18\]       .024     4.83 \[4.35‐5.22\]      6.57 \[5.42‐8.45\]      \<.001
  HbA1C, %                          5.60 \[5.28‐5.93\]        5.70 \[5.50‐6.90\]       .271     5.65 \[5.38‐5.93\]      6.00 \[5.60‐7.30\]      \<.001
  BUN, mmol/L                       4.14 \[3.70‐5.64\]        5.47 \[4.19‐6.46\]       .068     5.16 \[4.68‐5.92\]      5.12 \[4.52‐6.56\]      .566
  Serum creatinine, μmol/L          62.8 \[53.3‐72.6\]        68.5 \[61.4‐81.8\]       .063     65.6 \[57.8‐74.4\]      74.6 \[66.0‐81.1\]      .001
  Uric acid, μmol/L                 350.0 \[292.5‐396.3\]     322.0 \[294.0‐393.0\]    .583     331.5 \[271.0‐373.0\]   365.0 \[297.0‐449.0\]   .022
  Na+, mmol/L                       141.5 \[139.9‐142.7\]     139.8 \[138.5‐141.0\]    .021     142.0 \[140.1‐142.6\]   139.9 \[137.9‐142.6\]   .003
  K+, mmol/L                        4.00 \[3.73‐4.25\]        4.20 \[3.85‐4.40\]       .035     3.80 \[3.70‐4.10\]      4.10 \[3.80‐4.35\]      .012
  Serum albumin, g/L                39.5 \[38.1‐43.2\]        40.1 \[37.0‐41.7\]       .718     39.4 \[36.9‐41.4\]      40.2 \[38.1‐42.1\]      .104
  Free triiodothyronine, pg/mL      2.79 \[2.64‐3.01\]        2.52 \[2.35‐2.79\]       .008     2.95 \[2.70‐3.12\]      2.55 \[2.27‐2.77\]      \<.001
  Free tetraiodothyronine, ng/dL    1.06 \[0.98‐1.16\]        1.18 \[1.07‐1.31\]       .035     1.12 \[1.02‐1.25\]      1.14 \[1.07‐1.24\]      .59
  sTSH, uIU/mL                      1.85 \[1.12‐2.41\]        1.13 \[0.65‐1.45\]       .006     2.05 \[1.25‐3.25\]      1.17 \[0.62‐1.62\]      \<.001
  Troponin‐I, ng/mL                 0.00 \[0.00‐0.01\]        12.38 \[2.52‐71.95\]     \<.001   0.00 \[0.00‐0.02\]      6.56 \[0.39‐31.77\]     \<.001
  CKMB, ng/Ml                       0.60 \[0.01‐1.25\]        15.05 \[1.00‐105.48\]    .001     0.50 \[0.10‐0.80\]      14.00 \[2.90‐49.35\]    \<.001
  Fibrinogen, mg/dL                 254.0 \[237.5‐293.5\]     280.0 \[241.2‐333.9\]    .374     240.3 \[206.4‐299.4\]   283.1 \[257.0‐325.8\]   \<.001
  Medicine use                                                                                                                                  
  Aspirin, n (%)                    6 (30.0)                  20 (100.0)               \<.001   24 (50.0)               76 (89.4)               \<.001
  Clopidogrel, n (%)                3 (15.0)                  20 (100.0)               \<.001   4 (8.3)                 65 (76.5)               \<.001
  Ticagrelor, n (%)                 0 (0.0)                   0 (0.0)                  1.000    0 (0.0)                 16 (18.8)               .001
  ACEI/ARB, n (%)                   4 (20.0)                  6 (30.0)                 .465     10 (20.8)               53 (62.4)               \<.001
  Statin, n (%)                     12 (60.0)                 20 (100.0)               .006     33 (68.8)               76 (89.4)               .003
  β‐blocker                         4 (20.0)                  11 (55.0)                .022     14 (29.2)               60 (70.6)               \<.001
  CCB, n (%)                        6 (30.0)                  1 (5.0)                  .096     11 (22.9)               8 (9.4)                 .033
  Prognostic data                                                                                                                               
  LVEDD, mm                         45.0 \[44.0‐49.0\]        46.0 \[44.3‐49.8\]       .478     46.0 \[43.0‐50.0\]      48.5 \[46.0‐50.8\]      .001
  LVEF, %                           71.0 \[66.5‐72.5\]        65.5 \[59.3‐73.8\]       .069     67.0 \[66.0‐73.0\]      55.0 \[50.0‐65.0\]      \<.001
  NT‐BNP, pg/mL                     54.4 \[16.0‐109.9\]       760.3 \[417.6‐1171.0\]   .002     45.1 \[26.7‐89.3\]      311.1 \[176.1‐869.9\]   \<.001
  Cardiac shock, n (%)              0 (0.0)                   0 (0.0)                  1.000    0 (0.0)                 3 (3.5)                 .479
  Malignant arrhythmia, n (%)       0 (0.0)                   2 (10.0)                 .468     0 (0.0)                 4 (4.7)                 .319
  Death, n (%)                      0 (0.0)                   0 (0.0)                  1.000    0 (0.0)                 1 (1.2)                 .771
  Hospital time, d                  3.50 \[3.00‐6.00\]        7.50 \[6.00‐9.00\]       \<.001   4.00 \[3.00‐6.00\]      11.00 \[6.00‐15.00\]    \<.001

Abbreviations: ACEI/ARB, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers; ALT, alanine aminotransferase; AMI, acute myocardial infarction; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CCB, calcium antagonist; CKMB, creatine kinase MB; ESR, erythrocyte sedimentation rate; HbA1C, glycosylated haemoglobin; HDL‐C, high density lipoprotein cholesterol; LDL‐C, low density lipoprotein cholesterol; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NT‐BNP, N‐terminal proB‐type natriuretic peptide; sTSH, thyroid‐stimulating hormone.
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![qRT‐PCR analysis of expression of 6 kinds of circulating exosomal lncRNAs (ENST00000553425.1, ENST00000556024.1, ENST00000556899.1, ENST00000597609.1, ENST00000603310.1 and ENST00000575985.1) were selected in the first validation](JCMM-24-9388-g003){#jcmm15589-fig-0003}

3.3. Second validation of circulating exosomal lncRNA {#jcmm15589-sec-0012}
-----------------------------------------------------

The second validation was performed in 85 AMI patients and 48 controls, and their clinical characteristics are shown in Table [1](#jcmm15589-tbl-0001){ref-type="table"}. Their demographic characteristics were mostly well balanced between the two groups. In the second validation, lncRNA ENST00000556899.1 (*P* = .040, fold change = 2.49) (Figure [4A](#jcmm15589-fig-0004){ref-type="fig"}) and lncRNA ENST00000575985.1 (*P* = .008, fold change = 3.14) (Figure [4A](#jcmm15589-fig-0004){ref-type="fig"}) were shown to be significantly up‐regulated in AMI patients when compared with controls. Receiver operating characteristic (ROC) curve analysis of circulating exosomal lncRNA ENST00000556899.1 showed an AUC = 0.661 ± 0.051 (95% CI 0.560‐0.762, *P* = .002) for all AMI patients (Figure [4B](#jcmm15589-fig-0004){ref-type="fig"}); AUC = 0.648 ± 0.056 (95% CI 0.538‐0.758, *P* = .010) for ST‐segment elevation myocardial infarction (STEMI) patients (Figure [4C](#jcmm15589-fig-0004){ref-type="fig"}); and AUC = 0.684 ± 0.060 (95% CI 0.565‐0.802, *P* = .006) for non‐ST‐segment elevation myocardial infarction (NSTEMI) patients (Figure [4D](#jcmm15589-fig-0004){ref-type="fig"}). ROC curve analysis of circulating exosomal lncRNA ENST00000575985.1 showed an AUC = 0.751 ± 0.045 (95% CI 0.661‐0.838, *P* \< .001) for all AMI patients (Figure [4B](#jcmm15589-fig-0004){ref-type="fig"}); AUC = 0.760 ± 0.048 (95% CI 0.666‐0.853, *P* \< .001) for STEMI patients (Figure [4C](#jcmm15589-fig-0004){ref-type="fig"}); and AUC = 0.698 ± 0.059 (95% CI 0.581‐0.814, *P* = .003) for NSTEMI patients (Figure [4D](#jcmm15589-fig-0004){ref-type="fig"}).

![Circulating exosomal lncRNA ENST00000575985.1 and ENST00000556899.1 in the second validation. A, qRT‐PCR analysis of expression of ENST00000575985.1 and ENST00000556899.1; B, receiver operating characteristic (ROC) curves analyses of ENST00000575985.1 and ENST00000556899.1 for all AMI; C: ROC curves analyses for STEMI; D: ROC curves analyses for NSTEMI. AMI, acute myocardial infarction; STEMI, ST‐segment elevation myocardial infarction; and NSTEMI, non--ST‐segment elevation myocardial infarction](JCMM-24-9388-g004){#jcmm15589-fig-0004}

Association between circulating exosomal lncRNAs and clinical parameters.

Circulating exosomal lncRNA ENST00000575985.1 showed more significant relationships with clinical parameters when compared with lncRNA ENST00000556899.1. LncRNA ENST00000575985.1 showed association with inflammatory biomarkers, including C‐reactive protein (CRP) (*r* = .357, *P* \< .001), erythrocyte sedimentation rate (ESR) (*r* = .216, *P* = .037), leukocyte count (*r* = .228, *P* = .008) and neutrophil count (*r* = .207, *P* = .017), and also showed correlation with prognostic indicators, including LVEDD (*r* = .243, *P* = .008), LVEF (*r* = −.358, *P* \< .001), NT‐BNP (*r* = .305, *P* = .002) and hospital time (*r* = .287, *P* = .001). Both of the two lncRNAs were associated with myocardial damage markers, including TNI (for lncRNA ENST00000575985.1, *r* = .369, *P* \< .001; for lncRNA ENST00000556899.1, *r* = .313, *P* \< .001), CKMB (for lncRNA ENST00000575985.1, *r* = .222, *P* = .010; for lncRNA ENST00000556899.1, *r* = .213, *P* = .014) and aspartate aminotransferase (AST) (for lncRNA ENST00000575985.1, *r* = .265, *P* = .002; for lncRNA ENST00000556899.1, *r* = .211, *P* = .016) (Table [2](#jcmm15589-tbl-0002){ref-type="table"}). In multivariate logistic model, after adjusting for age, gender, BMI, hypertension and diabetes history, smoking and drinking habits, the circulating exosomal lncRNA ENST00000575985.1 was positively associated with the risk of severe heart failure in AMI patients (OR = 1.046, 95%CI 1.005‐1.089, *P* = .029) (Table [3](#jcmm15589-tbl-0003){ref-type="table"}).

###### 

Associations between circulating exosomal lncRNA ENST00000575985.1 and ENST00000556899.1 with clinical parameters

                             lncRNA ENST00000575985.1   lncRNA ENST00000556899.1               
  -------------------------- -------------------------- -------------------------- ----------- ------------
  Age                        .018                       .835                       .02         .822
  Hospital time              **.287**                   **.001**                   .108        .217
  LVEDD                      **.243**                   **.008**                   .136        .14
  LVEF                       **−.358**                  **\<.001**                 −.106       .251
  Heart rate                 **.198**                   **.023**                   .041        .64
  Systolic blood pressure    **−.185**                  **.033**                   −.065       .457
  Diastolic blood pressure   −.075                      .388                       .048        .582
  Body mass index            **−.209**                  **.042**                   −.066       .528
  C‐reactive protein         **.357**                   **\<.001**                 .089        .347
  ESR                        **.216**                   **.037**                   .065        .534
  Leukocyte                  **.228**                   **.008**                   .057        .516
  Neutrophil                 **.207**                   **.017**                   .157        .072
  Lymphocyte                 −.102                      .243                       −.039       .659
  Hemoglobin                 .081                       .352                       .037        .674
  Platelets                  .028                       .745                       **−.182**   **.036**
  AST                        **.265**                   **.002**                   **.211**    **.016**
  ALT                        **.285**                   **.001**                   .17         .052
  Total cholesterol          .114                       .193                       .099        .261
  HDL‐C                      **−.193**                  **.03**                    **−.184**   **.038**
  LDL‐C                      .125                       .16                        .035        .693
  Triglycerides              .13                        .146                       .026        .772
  Fast glucose               **.273**                   .002                       .052        .564
  HbA1C                      .175                       .094                       .105        .318
  BUN                        .068                       .442                       −.006       .946
  Serum creatinine           .158                       .071                       **.214**    **.014**
  Uric acid                  .172                       .092                       .117        .252
  Na+                        −.12                       .171                       .011        .899
  K+                         .146                       .097                       −.028       .75
  Serum albumin              .031                       .725                       −.041       .644
  Free triiodothyronine      −.148                      .164                       −.084       .433
  Free tetraiodothyronine    −.031                      .77                        .022        .839
  sTSH                       −.171                      .109                       −.161       .131
  Troponin‐I                 **.369**                   **\<.001**                 **.313**    **\<.001**
  CKMB                       **.222**                   **.010**                   **.213**    **.014**
  Fibrinogen                 **.178**                   **.044**                   .004        .961
  NT‐BNP                     **.305**                   **.002**                   **.334**    **.001**

Abbreviations: ALT, alanine aminotransferase; and sTSH, thyroid‐stimulating hormone; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CKMB, creatine kinase MB; ESR, erythrocyte sedimentation rate; HbA1C, glycosylated haemoglobin; HDL‐C, high density lipoprotein cholesterol; LDL‐C, low density lipoprotein cholesterol; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NT‐BNP, N‐terminal proB‐type natriuretic peptide. Bold indicates statistical significant value.
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###### 

Multivariate logistic analysis of circulating exosomal lncRNAs in AMI patients[^a^](#jcmm15589-note-0006){ref-type="fn"}

                           ENST00000575985.1   ENST00000556899.1                                    
  ------------------------ ------------------- ------------------- ---------- ------- ------------- ------
  Heart failure            **1.046**           **1.005‐1.089**     **.029**   0.989   0.963‐1.016   .414
  long‐term hospitalized   1.022               0.956‐1.093         .521       1.002   0.970‐1.036   .890
  MACE                     0.983               0.928‐1.042         .572       0.958   0.877‐1.047   .345

Abbreviations: AMI, acute myocardial infarction; MACE, major adverse cardiovascular events. Bold indicates statistical significant value.

The model was adjusting for age, gender, BMI, hypertension and diabetes history, smoking and drinking habits.

John Wiley & Sons, Ltd

4. DISCUSSION {#jcmm15589-sec-0013}
=============

Extracellular vesicles (EVs)---particularly exosomes and microvesicles (MVs)---are attracting considerable interest in the cardiovascular field as the wide range of their functions is recognized in various cardiovascular diseases, including ischaemic heart disorders.[^20^](#jcmm15589-bib-0020){ref-type="ref"} These capabilities contain transporting regulatory molecules including different RNA species, lipids and proteins through the extracellular space including blood and delivering these cargos to recipient cells to modify cellular activity.[^20^](#jcmm15589-bib-0020){ref-type="ref"} EVs powerfully stimulate angiogenesis and may protect the heart against AMI. The present study revealed some interesting findings, in which the circulating exosomal lncRNAs might act as potential biomarkers for patients with AMI, especially the lncRNA ENST00000575985.1, and the lncRNA ENST00000575985.1 might be associated with the prognosis of AMI.

Exosomes as main EVs are around 100 nm in diameter and contain various informational particles, such as lncRNAs, miRNAs, mRNAs and proteins.[^20^](#jcmm15589-bib-0020){ref-type="ref"} Notably, exosomes are easily accessible in the extracellular fluids of the body, which have been shown to be as potential biomarkers in heart diseases.[^20^](#jcmm15589-bib-0020){ref-type="ref"}, [^21^](#jcmm15589-bib-0021){ref-type="ref"}, [^22^](#jcmm15589-bib-0022){ref-type="ref"} Previous studies have demonstrated that exosomal ncRNAs could serve as diagnostic biomarkers in various tumour and cardiovascular diseases.[^20^](#jcmm15589-bib-0020){ref-type="ref"}, [^22^](#jcmm15589-bib-0022){ref-type="ref"}, [^23^](#jcmm15589-bib-0023){ref-type="ref"}, [^24^](#jcmm15589-bib-0024){ref-type="ref"} EVs of different sources may be useful biomarkers of cardiovascular disease identities such as AMI and heart failure.[^20^](#jcmm15589-bib-0020){ref-type="ref"} Serum exosomal miRNA‐320d is a promising non‐invasive diagnostic biomarker for distinguishing metastatic from non‐metastatic colorectal cancer (CRC).[^23^](#jcmm15589-bib-0023){ref-type="ref"} Besides, the combination of miR‐320d and carcinoembryonic antigen had an AUC of 0.804 for the diagnosis of patients with metastatic CRC.[^23^](#jcmm15589-bib-0023){ref-type="ref"} Additionally, serum exosomal lncRNA MIAT levels were significantly higher in gastric cancer (GC) patients than in gastric adenoma patients and healthy controls.[^24^](#jcmm15589-bib-0024){ref-type="ref"} Interestingly, gastric adenoma patients with higher serum exosomal MIAT expression were more prone to develop GC,[^24^](#jcmm15589-bib-0024){ref-type="ref"} indicating serum exosomal lncRNA MIAT might serve as a promising novel biomarker for monitoring the progression of GC. Exosomal miRNA might act as diagnostic biomarkers in AMI and play an important role in the pathophysiology of AMI.[^25^](#jcmm15589-bib-0025){ref-type="ref"}, [^26^](#jcmm15589-bib-0026){ref-type="ref"} However, there is no evidence regarding the exact role of exosomal lncRNAs in AMI. The lncRNAs present in exosomes are highly stable because of the protective impact of the exosomal lipid bilayers on enzymatic degradation. So the present study sought to firstly investigate the role of circulating exosomal lncRNAs in patients with AMI.

Through sequencing profiles and twice qRT‐PCR validations, circulating exosomal lncRNAs ENST00000556899.1 and ENST00000575985.1 showed significant up‐regulation in AMI. Especially ENST00000575985.1, it yielded an area under the curve value of 0.751 in AMI and was associated with many clinical parameters, including inflammatory biomarkers, prognostic indicators and myocardial damage markers, and even the risk of heart failure in AMI. ENST00000575985.1, also named as RP5‐1050D4.4‐001 (Ensembl Human GRCh37. p13) and AC004771.4‐201 (Ensembl Human GRCh38. p13), was a novel transcript antisense to calmodulin‐binding transcription factor 2 (CAMTA2) gene. No research on ENST00000575985.1 was conducted yet. However, several studies have reported the role of CAMTA2 in cardiovascular diseases.[^27^](#jcmm15589-bib-0027){ref-type="ref"}, [^28^](#jcmm15589-bib-0028){ref-type="ref"} ENST00000556899.1, which is also named as CTD‐2536I1.1‐001 (Ensembl Human GRCh37. p13) and LINC01197‐203 (Ensembl Human GRCh38. p13), was a long intergenic non‐protein coding RNA 1197. LINC01197 was reported to be associated with pancreatic cancer.[^29^](#jcmm15589-bib-0029){ref-type="ref"}, [^30^](#jcmm15589-bib-0030){ref-type="ref"} Finally, further studies are warranted to reveal the role of circulating exosomal lncRNAs ENST00000556899.1 and ENST00000575985.1 in AMI.

In summary, our findings have, for the first time, demonstrated that circulating exosomal lncRNAs ENST00000556899.1 and ENST00000575985.1 are elevated in patients with AMI, functioning as potential biomarkers for predicting the prognosis of AMI. However, the present study has some limitations: (a) as a clinical observation study, the internal mechanism of circulating exosomal lncRNAs in AMI should be further investigated; (b) included sample size in this work was small with lacked follow‐up after discharge, and thus, larger sample size study with long‐term follow‐up should be conducted to verify these findings.
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